DNTH · Nasdaq · ·
Next earnings: November 4, 2026
$87.18-0.8%Sep 29 close
Dianthus Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $284K | $1.3M | -78.58% |
| Profit | -$50.2M | -$31.6M | -58.76% |
| Profit per share | -$0.90 | -$0.88 | -2.27% |
| Free Cash Flow | -$49.2M | -$23.9M | -105.37% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our strong execution in the first half of 2026 reflects the continued focus and discipline of the Dianthus team as we advance both claseprubart and DNTH212 for severe autoimmune diseases,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
DNTH212 is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. By targeting both the innate and adaptive immune systems via two clinically validated pathways that are known drivers of autoimmune disease pathogenesis, this complementary and differentiated approach has the potential to address multiple autoimmune indications with improved outcomes. Dianthus is building a rheumatology franchise with DNTH212 and has selected Sjögren’s Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM) as the first three prioritized indications for clinical development. A two-part Phase 1 study in China in healthy volunteers (Part A) and patients with systemic lupus erythematosus (Part B) is ongoing, with healthy volunteer data expected by YE’26. DNTH212 is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Dianthus Therapeutics, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Dianthus Therapeutics, Inc. has no earnings call transcript available.